Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy Virtual 2020 | Drug resistance in multiple myeloma

Keith Stewart • 30 Apr 2020
COMy Virtual 2020
Multiple Myeloma Iberdomide Lenalidomide Pomalidomide Thalidomide

Keith Stewart, MB, ChB, Mayo Clinic, Rochester, MN, gives us an overview of drug resistance with immunomodulatory therapies in multiple myeloma (MM). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Keith Stewart

The future of myeloma therapy
Brian Walker et al. • 15 Apr 2023
10:38
Day 2 wrap-up: pushing myeloma boundaries
Gareth Morgan et al. • 27 Mar 2022
11:10
Day 1 highlights: peripheral blood MRD, AB amyloid treatment, single-cell & metabolomics
Faith Davies et al. • 26 Mar 2022
3:09
Immunotherapy in myeloma - where are we?
Keith Stewart • 30 Apr 2020

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals